Plavitore Tablet (Clopidogrel Hydrogen Sulfate)

Adult dose

○ Adults 1. For patients with ischemic stroke, myocardial infarction, or peripheral arterial disease, administer 75 mg of clopidogrel orally once daily. 2. For patients with acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), start with a loading dose of 300 mg of this drug once daily on the first day of treatment, followed by a maintenance dose of 75 mg once daily orally. In this case, aspirin 75 ～ 325 mg should be coadministered with this drug once daily. 3. For patients with atrial fibrillation, administer 75 mg of this drug orally once daily. In this case, aspirin 75 ～ 100 mg should be coadministered with this drug once daily. ○ Patients with renal impairment: Treatment experience in patients with renal impairment is limited. ○ Patients with hepatic impairment: Treatment experience in patients with moderate hepatic disease and a bleeding diathesis is limited. This drug may be administered with or without food.

This drug prevents platelets from aggregating, thereby preventing thrombus formation. Individuals with reduced enzyme activity of CYP2C19 may experience diminished effects of this drug and a higher risk of issues with the heart or blood vessels, thus additional caution is advised. It is not recommended to use this drug in conjunction with medications that increase CYP2C19 activity, as this may increase the risk of bleeding. Patients allergic to this drug or its components, those with severe bleeding, severe liver dysfunction, nursing women, or those with specific genetic disorders such as lactose intolerance should not take this medication. Patients at risk of bleeding or those who are scheduled for surgery should exercise caution when taking this drug and inform their doctor immediately if bleeding symptoms occur. Particularly, caution should be exercised when taken in conjunction with anticoagulants like warfarin, as this increases the risk of bleeding. This medication can rarely cause thrombocytopenia or severe hematological adverse reactions, so immediate medical evaluation is necessary if symptoms of infection or bleeding emerge. Various side effects like dyspepsia, diarrhea, headache, and rash can occur, and if symptoms are severe, consultation with a physician is advised. During pregnancy, this drug should only be used when absolutely necessary, taking fetal effects into consideration, and may be discontinued prior to delivery due to the risk of bleeding. In breastfeeding cases, since this drug can be excreted in breast milk, consult with a physician regarding whether to continue breastfeeding. Elderly patients or those with impaired kidney function are at increased risk of bleeding, and dosage adjustments and monitoring are required. Overdose may increase the risk of bleeding, so it is essential to adhere to the prescribed dosage, and in cases of severe bleeding, emergency measures such as platelet transfusion may be necessary. The safety and efficacy of this drug in children have not been sufficiently established, thus it should be used cautiously. During the course of this medication, it is vital to inform healthcare providers about the use of this drug before any surgery, trauma, or other medications. Finally, store this drug out of the reach of children and avoid transferring it to other containers.

• Hemorrhage
• gastrointestinal bleeding
• purpura
• contusion
• hematoma
• epistaxis
• hematoma
• hematuria
• intraocular hemorrhage
• intracranial hemorrhage

This drug should be stored in a tightly closed container to protect it from air and moisture. It is recommended to maintain storage temperature between 1 to 30 degrees Celsius.

Appearance

Pink round film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle